Financial News
All news about Sanofi-Aventis S.A.
3 Reasons to Buy Novavax Stock, and 1 Reason to Sell
January 21, 2021
From Motley Fool
The Biggest Drug Competition in 2021 (Hint: It Isn't COVID Vaccines)
January 17, 2021
From Motley Fool
From Motley Fool
‘Manufacturers and middlemen have created a vicious cycle of price increases’: Mark Cuban pledges to sell this $225 medication for $20
January 15, 2021
From MarketWatch
Is Novavax's Growth Story Over?
January 15, 2021
From Motley Fool
Why Lexicon Pharmaceuticals Stock Doubled and Then Some on Thursday
January 14, 2021
From Motley Fool
Is Regeneron Stock Heading to $590?
January 13, 2021
From Motley Fool
Sanofi Spins Off an Industry-Leading Business
January 12, 2021
From Motley Fool
Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
January 12, 2021
From PR Newswire
3 Coronavirus Stocks to Stay Miles Away From in 2021
January 12, 2021
From Motley Fool
Up 1,530% in 2020, Is Vaxart Still a Buy?
January 08, 2021
From Motley Fool
Moderna Hires Amgen Executive As Chief Commercial Officer To Bolster Vaccine Marketing
January 07, 2021
From Benzinga
A Specialty Consolidator: Biopharma Aytu Looks To Acquisitions And Licensing To Propel Growth Through 2021
January 06, 2021
From Benzinga
3 Recession-Proof Healthcare Stocks to Buy for 2021
January 05, 2021
From Motley Fool
Market Briefing For Tuesday, Jan. 5
January 05, 2021
From Blogs - TalkMarkets
The Worst Mistake Novavax Investors Can Make Right Now
January 04, 2021
From Motley Fool
3 Top Biotech Buyout Candidates in 2021
January 04, 2021
From Motley Fool
5 Big ETF Stories Of 2020 Worth Watching In 2021
January 03, 2021
From Blogs - TalkMarkets
Week In Review: How Trump's Policies Moved Stocks -Saturday, Dec. 26
December 26, 2020
From Blogs - TalkMarkets
Here's What Investors Need to Know About Sanofi and GlaxoSmithKline's COVID Vaccine Setback
December 22, 2020
From Motley Fool
Better Coronavirus Stock: Pfizer vs. BioNTech
December 19, 2020
From Motley Fool
Where Will Novavax Be in 1 Year?
December 19, 2020
From Motley Fool
FDA Refuses to Approve Novartis' $9.7 Billion Cholesterol Drug for Now
December 18, 2020
From Motley Fool
2 Reasons It's Not Too Late to Buy BioNTech
December 17, 2020
From Motley Fool
Why AstraZeneca's and Sanofi's Bad News Could Be Great News for Pfizer and Moderna
December 16, 2020
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.